Status:
WITHDRAWN
Does Intramyometrial Oxytocin Improve Outcome in Elective Cesarean Delivery?
Lead Sponsor:
University of Saskatchewan
Conditions:
Postpartum Hemorrhage
Uterine Atony
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
Oxytocin use has become routine practice in elective cesarean delivery to promote uterine contraction and reduce blood loss. However, there is a lack of consensus regarding the best dose of oxytocin a...
Eligibility Criteria
Inclusion
- Healthy Parturients
- Elective cesarean Delivery
- Term (\> 37 wks gestational age) as defined by ultrasound or last menstrual period
- Singleton fetus
- Vertex presentation
- Age \> 18
- BMI \< 40
- Height \> 5'2" and \< 5"8"
- Written informed consent
Exclusion
- Placenta previa
- Multiple gestation
- Preeclampsia
- Gestational Diabetes or pre-existing diabetes
- Macrosomia (estimated fetal weight prior to delivery)
- Polyhydramnios
- Oligohydramnios
- Uterine fibroids
- More than 2 previous cesarean deliveries
- Suspected adherent placenta (acreta/increta/percreta)
- Planned general anesthesia
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01252342
Start Date
August 1 2011
End Date
April 1 2012
Last Update
January 11 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal University Hospital
Saskatoon, Saskatchewan, Canada, S7N 0W8